Thermosome Establishes High-Profile Clinical Advisory Board


- Leveraging the transformative potential of TSL-based tumor targeting

- Supporting the progress of Thermosome's clinical candidate THE001

Munich, Germany – September 19, 2023 – Thermosome, a drug development company specializing in targeted tumor therapies, today announced the formation of a Clinical Advisory Board to support the advancement of its lead compound THE001 through clinical development.